Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

摘要

NZ 597325 Disclosed is the use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligo saccharides (sugars) at Asn297, for the manufacture of a medicament for the treatment of cancer in combination with fludarabine and/or mitoxantrone, wherein said antibody is a humanised B-Ly1 antibody, and the humanized B-Ly1 antibody is characterised in comprising an amino acid sequence of the variable region of the heavy chain (VH) of SEQ ID NO: 7, and in comprising an amino acid sequence of the variable region of the light chain (VL) of SEQ ID NO: 20; and wherein a) when the humanised B-Ly1 antibody is administered in combination with fludarabine, the antibody is administered in a dosage of 800 to 1600 mg on day 1 of up to six or seven 3-to 4-week-dosage-cycles, and fludarabine is administered in a dosage of 20mg/m2 to 30 mg/m2 on day 1, 2 and 3 of up to six or seven 4-week-dosage-cycles, or b) when the humanised B-Ly1 antibody is administered in combination with fludarabine and cyclophosphamide, the antibody in a dosage of 800 to 1600 mg on day 1 of up to six or seven 3-to 4-week-dosage-cycles, fludarabine is administered in a dosage of 20mg/m2 to 30 mg/m2 on day 1, 2 and 3 of up to six or seven 4-week-dosage-cycles, and cyclophosphamide is administered in a dosage of 200 mg/m2 to 300 mg/m2 on day 1, 2 and 3 of up to six or seven 4-week-dosage-cycles.